Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL

Complete title: A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn(R) (Pralatrexate) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Research Study Number 20141037
 
Principal Investigator Andrei Shustov, MD
 
Phase II

Research Study Description

This study is to evaluate the effect of leucovorin in preventing or reducing Folotyn-related Grade 3 or higher oral mucositis.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20141037
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Hematologic Malignancies; Lymphoma; Lymphoma, Non-Hodgkin (NHL); Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials